Ask AI
ProCE Banner Activity

ASCENT-04/KEYNOTE-D19: Patient-Reported Outcomes of 1L Sacituzumab Govitecan vs CT + Pembrolizumab in PD-L1–Positive Advanced TNBC

Conference Coverage
Slideset

Among patients with previously untreated PD-L1–positive metastatic triple-negative breast cancer in the phase III ASCENT-04/KEYNOTE-D19 trial, sacituzumab govitecan plus pembrolizumab maintained baseline quality of life and provided improvement in several QoL domains vs chemotherapy plus pembrolizumab.

Released: October 28, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly